Cat. No.: DAA-001232
Product Information | |
---|---|
Product Name | Human Leptin ELISA Kit |
Species | Human |
Description | Human Leptin ELISA kit is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Leptin protein in human serum, plasma and cell culture supernatants. It uses our proprietary ELISA technology. Quantitate human Leptin with 4.65 pg/mL sensitivity. ELISA technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our ELISA plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. |
Sample Types | Cell Culture Supernatant, Serum, Plasma, Hep Plasma, Edta Plasma, Cit Plasma |
Detection Range | 15.63 pg/mL - 1000 pg/mL |
Sensitivity | 4.65 pg/mL |
Target Information | |
---|---|
Target Name | LEP |
UniProt No. | P41159 |
Gene ID | 3952 |
Target Description | May function as part of a signaling pathway that acts to regulate the size of the body fat depot. An increase in the level of LEP may act directly or indirectly on the CNS to inhibit food intake and/or regulate energy expenditure as part of a homeostatic mechanism to maintain constancy of the adipose mass. |
Alternative Names | FLJ94114; LEP; LEP_HUMAN; LEPD; Leptin; Leptin (murine obesity homolog); Leptin (obesity homolog, mouse); Leptin Murine Obesity Homolog; Leptin Precursor Obesity Factor; OB; Obese protein; Obese, mouse, homolog of; Obesity; Obesity factor; Obesity homolog mouse; Obesity Murine Homolog Leptin; OBS; OTTHUMP00000212285 |
Shipping & Storage | |
---|---|
Sipping | Shipping on dry ice. |
Storage | Store at +4°C. Please refer to protocols. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.